Literature DB >> 4019660

Determination of dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection.

T East, D Dye.   

Abstract

Sensitive methods were developed for the analysis of dextromethorphan (I) and two metabolites, (+)-17-methyl-morphinan-3-ol (II) and (+)-morphinan-3-ol (III), in plasma as well as dextromethorphan and three metabolites II, III and (+)-3-methoxymorphinan (IV) in urine using high-performance liquid chromatography followed by detection with a fluorometer. Dextromethorphan and its metabolites were extracted from plasma and urine and separated in the reversed-phase mode. The practical lower limits of determination for I, II, and III in plasma were 0.5, 5, and 5 ng/ml, respectively; for I, II, III, and IV in urine, the limits were 20 ng/ml, 0.6 microgram/ml, 0.5 microgram/ml, and 15 ng/ml, respectively. The linearity of the calibration graphs was excellent (r varied from 0.9994 to 0.9999) over concentration ranges of two orders of magnitude.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4019660     DOI: 10.1016/0378-4347(85)80074-8

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man.

Authors:  O Mortimer; B Lindström; H Laurell; U Bergman; A Rane
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

2.  Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.

Authors:  Christian Funck-Brentano; Pierre-Yves Boëlle; Céline Verstuyft; Célia Bornert; Laurent Becquemont; Jean-Marie Poirier
Journal:  Eur J Clin Pharmacol       Date:  2005-11-17       Impact factor: 2.953

3.  Minor and clinically non-significant interaction between toloxatone and amitriptyline.

Authors:  S Vandel; G Bertschy; M C Perault; M Sandoz; S Bouquet; R Chakroun; S Guibert; B Vandel
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.